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Background: Habitual smoking has been associated with increased platelet reactivity, increased risk of thrombotic complications and greater 
efficacy of clopidogrel therapy over placebo. In the PLATO trial, ticagrelor compared to clopidogrel in patients with acute coronary syndromes (ACS) 
reduced the primary composite endpoint of vascular death, myocardial infarction and stroke, without increasing overall rates of major bleeding.
Methods: Smoking status was known in 18610 of the 18624 patients randomized. We investigated ischemic and bleeding outcomes of ticagrelor 
versus clopidogrel in habitual smokers (N=6678) and in ex/non smokers (N=11,932).
Results: Habitual smokers had an overall lower risk profile and more often ST elevation ACS. After adjustment for baseline differences, habitual 
smoking was associated with a higher incidence of definite stent thrombosis (adjusted HR 1.44 [95%CI 1.07-1.94]); there were no significant 
associations with other ischemic or bleeding endpoints. The effects of ticagrelor compared to clopidogrel were consistent regardless of smoking 
status (figure). There was no interaction between smoking status and the effects of treatment.
Conclusions: In ACS patients, prior habitual smoking is associated with a greater risk of subsequent stent thrombosis. The reduction of vascular 
death, myocardial infarction, stroke and stent thrombosis by ticagrelor compared to clopidogrel is consistent regardless of smoking habits.
 
